Imagine having a digital guardian that watches your health 24/7 using your smartwatch, shoes, and even your mattress. It spots tiny warning signs of a lung crisis before you even feel them. This allows doctors to step in early and change your treatment, keeping you out of the hospital.
COPD exacerbations and comorbidities are often underestimated and poorly managed, leading to high healthcare costs and poor patient prognosis. Current lung function assessments fail to capture the daily-life limitations and early warning signs of a crisis.
An AI-based platform featuring a Patient Management Tool (PMT) for doctors and a Disease Information Tool (DIT) for patients, powered by data from smartwatches, smartphones, smart mattresses, and smart-shoes.
If you are an RPM provider dealing with high hospital readmission rates for lung patients — this project developed AI analytics tools that predict exacerbations using smart sensors. This allows for proactive intervention instead of reactive emergency care.
If you are a wearable manufacturer dealing with a lack of clinical validation for your hardware — this project developed a system integrating smart-shoes and smart-mattresses into a clinical COPD workflow. This provides a proven use-case for specialized health sensors.
If you are an insurer dealing with the high costs of chronic lung disease complications — this project developed a validated AI platform to reduce exacerbation events. This directly lowers the healthcare costs associated with emergency COPD hospitalizations.
Based on available project data, specific pricing or cost-per-user details are not provided; the project focuses on clinical validation and development.
The project is currently in the clinical validation phase with two studies (Study A for development and Study B for effectiveness), suggesting it is moving toward scale but not yet fully deployed.
Based on available project data, specific licensing terms are not mentioned, though the project involves 7 industry partners and 4 SMEs who likely share in the IP development.
It integrates via two specific interfaces: a Patient Management Tool (PMT) for clinicians and a Disease Information Tool (DIT) for patients and caregivers.
The project period runs from 2022-09-01 to 2027-02-28, indicating that final validation and potential market entry would occur toward the end of this window.
The consortium is heavily weighted toward commercialization, with an industry ratio of 47% (7 industry partners, including 4 SMEs). This strong private-sector presence, combined with 3 universities and 4 research centers across 6 countries, suggests a high likelihood of the technology transitioning from clinical trials to a commercial product.
Contact Università di Pisa for details on the AI platform validation results.
Contact us to explore licensing opportunities for the TOLIFE AI analytics tools.
